Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-PATH: TAHP and AHP in HER2+ Early Breast Cancer
NCT03881878Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- May 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in HER2-positive breast cancer (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Pathologic Complete Response rate. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03881878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881878.